These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35986430)

  • 21. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
    Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
    Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
    Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
    Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
    Burns SS; Chang LS
    Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
    Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
    J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma.
    Antonescu CR; Dickson BC; Sung YS; Zhang L; Suurmeijer AJH; Stenzinger A; Mechtersheimer G; Fletcher CDM
    Am J Surg Pathol; 2020 Dec; 44(12):1677-1684. PubMed ID: 32991341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    Laraba L; Hillson L; de Guibert JG; Hewitt A; Jaques MR; Tang TT; Post L; Ercolano E; Rai G; Yang SM; Jagger DJ; Woznica W; Edwards P; Shivane AG; Hanemann CO; Parkinson DB
    Brain; 2023 Apr; 146(4):1697-1713. PubMed ID: 36148553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
    ; Allaway R; Angus SP; Beauchamp RL; Blakeley JO; Bott M; Burns SS; Carlstedt A; Chang LS; Chen X; Clapp DW; Desouza PA; Erdin S; Fernandez-Valle C; Guinney J; Gusella JF; Haggarty SJ; Johnson GL; La Rosa S; Morrison H; Petrilli AM; Plotkin SR; Pratap A; Ramesh V; Sciaky N; Stemmer-Rachamimov A; Stuhlmiller TJ; Talkowski ME; Welling DB; Yates CW; Zawistowski JS; Zhao WN
    PLoS One; 2018; 13(6):e0197350. PubMed ID: 29897904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
    Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
    Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infratentorial meningioma in an 8-year-old child as first sign of neurofibromatosis type 2.
    Stettner GM; Rostasy KM; Ludwig HC; Merkler D; Fahsold R; Gärtner J
    Neuropediatrics; 2007 Feb; 38(1):29-31. PubMed ID: 17607601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
    Hadfield KD; Smith MJ; Urquhart JE; Wallace AJ; Bowers NL; King AT; Rutherford SA; Trump D; Newman WG; Evans DG
    Oncogene; 2010 Nov; 29(47):6216-21. PubMed ID: 20729918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contiguous conventional and plexiform schwannomas. Report of two cases.
    White JB; Scheithauer BW; Amrami KK; Babovic-Vuksanovic D; Spinner RJ
    J Neurosurg; 2006 Feb; 104(2):319-24. PubMed ID: 16509508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brainstem intraparenchymal schwannoma with genetic analysis: a case report and literature review.
    Ishigami D; Miyawaki S; Nakatomi H; Takayanagi S; Teranishi Y; Ohara K; Hongo H; Dofuku S; Kin T; Abe H; Mitsui J; Komura D; Katoh H; Ishikawa S; Saito N
    BMC Med Genomics; 2021 Aug; 14(1):205. PubMed ID: 34407809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurofibromatosis 2 in the pediatric age group.
    Mautner VF; Tatagiba M; Guthoff R; Samii M; Pulst SM
    Neurosurgery; 1993 Jul; 33(1):92-6. PubMed ID: 8355853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
    Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
    J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sporadic vestibular schwannoma: a molecular testing summary.
    Sadler KV; Bowers NL; Hartley C; Smith PT; Tobi S; Wallace AJ; King A; Lloyd SKW; Rutherford S; Pathmanaban ON; Hammerbeck-Ward C; Freeman S; Stapleton E; Taylor A; Shaw A; Halliday D; Smith MJ; Evans DG
    J Med Genet; 2021 Apr; 58(4):227-233. PubMed ID: 32576656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.
    Evans DG; Lye R; Neary W; Black G; Strachan T; Wallace A; Ramsden RT
    J Neurol Neurosurg Psychiatry; 1999 Jun; 66(6):764-7. PubMed ID: 10329751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene.
    Ogasawara N; Sasaki M; Ishiguro H; Itoh Y; Nojiri S; Kubota E; Wada T; Kataoka H; Kuwabara Y; Joh T
    Dig Endosc; 2009 Jul; 21(3):192-5. PubMed ID: 19691769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.